Brief: Benitec Biopharma Announces Successful Results From The Interim Analysis Of The BB-301 Pilot Dosing Study

Benitec Biopharma

24/02/2021 13:46

Feb 24 (Reuters) - Benitec Biopharma Inc  BNTC.O :
    * BENITEC BIOPHARMA ANNOUNCES SUCCESSFUL RESULTS FROM THE
INTERIM
ANALYSIS OF THE BB-301 PILOT DOSING STUDY
    * BENITEC BIOPHARMA  - BENITEC HAS SCHEDULED A SCIENTIFIC
ADVICE
MEETING IN FRANCE IN MAY 2021 TO REVIEW INTERIM DATA AND PHASE 1
CLINICAL TRIAL DESIGN
    * BENITEC BIOPHARMA INC - COMPANY CONTINUES TO PLAN FOR
INITIATION
OF FIRST-IN-HUMAN CLINICAL STUDY OF BB-301 IN OPMD PATIENTS IN
2022

Source text for Eikon:  ID:nPn6xb7s8a 
Further company coverage:  BNTC.O 

 ((Reuters.Briefs@thomsonreuters.com;))